JP4745971B2 - ＰＤＫ−１／Ａｋｔシグナル伝達インヒビター - Google Patents

ＰＤＫ−１／Ａｋｔシグナル伝達インヒビター Download PDF

Info

Publication number
JP4745971B2
JP4745971B2 JP2006534245A JP2006534245A JP4745971B2 JP 4745971 B2 JP4745971 B2 JP 4745971B2 JP 2006534245 A JP2006534245 A JP 2006534245A JP 2006534245 A JP2006534245 A JP 2006534245A JP 4745971 B2 JP4745971 B2 JP 4745971B2
Authority
JP
Japan
Prior art keywords
compound
phenyl
group
cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006534245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007527408A (ja
JP2007527408A5 (enExample
Inventor
チン−シー チェン，
Original Assignee
ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34576689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4745971(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション filed Critical ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション
Publication of JP2007527408A publication Critical patent/JP2007527408A/ja
Publication of JP2007527408A5 publication Critical patent/JP2007527408A5/ja
Application granted granted Critical
Publication of JP4745971B2 publication Critical patent/JP4745971B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006534245A 2003-10-03 2004-10-04 ＰＤＫ−１／Ａｋｔシグナル伝達インヒビター Expired - Fee Related JP4745971B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50861903P 2003-10-03 2003-10-03
US60/508,619 2003-10-03
US50981403P 2003-10-08 2003-10-08
US60/509,814 2003-10-08
PCT/US2004/032723 WO2005044130A1 (en) 2003-10-03 2004-10-04 Pdk-1/akt signaling inhibitors

Publications (3)

Publication Number Publication Date
JP2007527408A JP2007527408A (ja) 2007-09-27
JP2007527408A5 JP2007527408A5 (enExample) 2008-07-10
JP4745971B2 true JP4745971B2 (ja) 2011-08-10

Family

ID=34576689

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534245A Expired - Fee Related JP4745971B2 (ja) 2003-10-03 2004-10-04 ＰＤＫ−１／Ａｋｔシグナル伝達インヒビター

Country Status (9)

Country Link
EP (1) EP1696907B1 (enExample)
JP (1) JP4745971B2 (enExample)
KR (1) KR101217427B1 (enExample)
CN (1) CN1889949B (enExample)
CA (1) CA2566846C (enExample)
DK (1) DK1696907T3 (enExample)
ES (1) ES2420405T3 (enExample)
SI (1) SI1696907T1 (enExample)
WO (1) WO2005044130A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060079566A1 (en) 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
CA2613522A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
JP2009519336A (ja) 2005-12-13 2009-05-14 ワイス ジベンゾナフチリジン誘導体およびそれらの使用方法
JP5399262B2 (ja) * 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒおよびｆｘｒのモジュレーター
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
US20120108823A1 (en) * 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
RU2432112C1 (ru) * 2010-05-27 2011-10-27 Федеральное государственное учреждение "Саратовский научно-исследовательский институт травматологии и ортопедии" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "СарНИИТО" Минздравсоцразвития России) Способ прогнозирования послеоперационных осложнений у больных с дегенеративно-дистрофическими поражениями суставов нижних конечностей
DE102010049877A1 (de) * 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
CA2818871A1 (en) * 2010-11-24 2012-05-31 The Ohio State University Research Foundation Integrin-linked kinase inhibitors
US10028933B2 (en) * 2015-07-22 2018-07-24 Ohio State Innovation Foundation Compositions and methods for inhibiting the growth of multi-drug resistant microbes
CN116462606B (zh) * 2022-01-12 2025-11-28 南京宁丹新药技术股份有限公司 一类酰胺衍生化合物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104311A (en) 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
KR100263817B1 (ko) * 1993-11-30 2000-08-16 윌리암스 로저 에이 염증치료용 치환 피라졸일벤젠술폰아미드
US5660273A (en) * 1994-07-13 1997-08-26 Centrix, Inc. Single patient dose medicament dispenser with applicator
AU2003230836A1 (en) * 2002-04-08 2003-10-27 The Ohio State University Research Foundation Compounds and methods for inducing apoptosis in proliferating cells
US7201577B2 (en) * 2002-04-24 2007-04-10 Gosmile, Inc. Tooth whitener applicator and method

Also Published As

Publication number Publication date
EP1696907B1 (en) 2013-04-17
KR101217427B1 (ko) 2013-01-02
WO2005044130A1 (en) 2005-05-19
DK1696907T3 (da) 2013-06-24
CN1889949B (zh) 2010-06-16
EP1696907A1 (en) 2006-09-06
EP1696907A4 (en) 2007-09-05
JP2007527408A (ja) 2007-09-27
ES2420405T3 (es) 2013-08-23
CA2566846C (en) 2012-08-28
CN1889949A (zh) 2007-01-03
KR20060108651A (ko) 2006-10-18
CA2566846A1 (en) 2005-05-19
WO2005044130A9 (en) 2005-09-15
SI1696907T1 (sl) 2013-12-31

Similar Documents

Publication Publication Date Title
US8546441B2 (en) PDK-1/AKT signaling inhibitors
US8039502B2 (en) Anti-infective agents against intracellular pathogens
JP4745971B2 (ja) ＰＤＫ−１／Ａｋｔシグナル伝達インヒビター
RU2744975C2 (ru) Фенилатное производное, получение и фармацевтическая композиция и применение
Beyhan et al. Synthesis and anticonvulsant activity of some 2-pyrazolines derived from chalcones
RU2249593C2 (ru) Пиразолбензодиазепины в качестве ингибиторов cdk2, промежуточные соединения для их получения и фармацевтическая композиция, их содержащая
JP2009114188A (ja) 置換２−フェニルベンズイミダゾールの使用
JP2005528384A (ja) 増殖性細胞においてアポトーシスを誘導するための化合物および方法
US7868185B2 (en) Shp-2 inhibitors and pharmaceutical compositions comprising them
CN101514179A (zh) 吲哚酮亚乙基肼羰基化合物、其制备方法及其在医药上的应用
US6034099A (en) Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
EP3634403B1 (en) Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
US9156790B2 (en) Anticancer P21-activated kinase inhibitors
EP2642856B1 (en) Integrin-linked kinase inhibitors
EP3901142A1 (en) Pyrazolylbenzene-1,3-diols for diseases associated with g protein-coupled receptor 18 and in combination with transient receptor potential vanilloid 1
WO1997046515A1 (en) Substituted benzenes having nos inhibitory effects
MXPA04010411A (es) Derivados novedosos de piperidinil-alquilamino-piridacinona, un proceso para la preparcion de los mismos y composiciones faramceuticas que contienen esos compuestos.
JP2019501137A (ja) ４−オキソ−４，５−ジヒドロチアゾール誘導体、その調製方法及び使用
JPWO1999023069A1 (ja) Ｎｏｓ阻害作用を有する複素環化合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080520

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110317

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110509

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110512

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140520

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4745971

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees